Atara biotherapeutics announces positive results from pivotal phase 3 trial (allele) of tab-cel® at the 63rd american society of hematology (ash) annual meeting

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced efficacy and safety results from its phase 3 multicenter allele study investigating tabelecleucel (tab-cel®) for the treatment of epstein-barr virus positive post-transplant lymphoproliferative diseas
ATRA Ratings Summary
ATRA Quant Ranking